entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 05:39:00 - browse：594

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： It's time to get medical device identifiers over the finish line

hotspot

WSS

Mass General Brigham physicians react to latest merger step

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Scientists uncover potential path to treating deadly childhood tumor

Alzheimer's risk factor APOE4 may be a distinct form of the disease

hotspot

entertainment

entertainment

Apple is now the first public company to be valued at $3 trillion

First Opinion on colorectal cancer screening: letter and response

State Dept. review finds Biden bears some blame for Afghanistan failures

Leqembi, other new Alzheimer’s drugs require better biomarkers

23andMe had bad news about my health. I wish a person had delivered it

Drug companies' payments and gifts affect physicians' prescribing

ChatGPT in medicine: STAT answers readers' burning questions

Study: Black kids more likely to die after surgery than white kids

Cancer drug shortages should be causing more outrage

Scientists uncover potential path to treating deadly childhood tumor

entertainment

Charles Manson follower Leslie Van Houten released from prison after 53 years

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Drug companies' payments and gifts affect physicians' prescribing

Mass General Brigham physicians react to latest merger step

Hundreds died while taking an arthritis drug, but nobody alerted patients

focus

hotspot

hotspot

hotspot